Bristol-Myers Squibb Company Overview
| Company: | Bristol-Myers Squibb Company |
|---|---|
| CEO: | Dr. Christopher S. Boerner Ph.D. |
| Symbol: | BMY |
| Exchange: | NYSE |
| Industry: | Drug Manufacturers - General |
| Sector: | Healthcare |
| About |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's productslude Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York. |
-
Ranking:
25 among 3046 companies
-
Address:
430 East 29th Street
-
City | State | Zip | Country:
New York | NY | 10016 | US
-
Phone:
212 546 4000
-
Website:
-
Revenue
Net Income
Employees
Revenue by Segment
Revenue by Region
Income Statement
Operating Income
Research & Development
Tax Rate (%)
Assets & Liabilities | Cash Flow
Total Assets
Total Liabilities
Capital Expenditure
Ratios
Return on Equity (ROE)
Return on Assets (ROA)
Debt to Equity
Profitability
Gross Profit Margin (%)
Operating Income Margin (%)
Net Income Margin (%)
Earning Per Share
EBITDA
Free Cash Flow (FCF)
Valuation
Enterprise value
Enterprise value to Revenue
Enterprise value to EBITDA
Competitors’ Revenue
